Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-030 - Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
Presenter: Federico Cappuzzo- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-048 - Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
Presenter: Federico Cappuzzo- Abstract
Loading...
-
+
P2.14 - Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
- 17:15 - 19:15
- 8/08/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
-
+
P2.14-02 - TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
Presenter: Lorenza Landi- Abstract
Loading...
-
+
MA13 - Update on ROS1 Inhibitors and New Pathways
- 12:00 - 13:00
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Lorenza Landi, Jii Bum (Joy) Lee
-
+
Session Moderator
12:52 - 13:00 | Presenter: Lorenza Landi
- Abstract
Loading... -
+
Session Moderator
12:52 - 13:00 | Presenter: Jii Bum (Joy) Lee
- Abstract
Loading... -
+
MA13.01 - Session Introduction
12:00 - 12:01 | Presenter: Lorenza Landi
- Abstract
Loading... -
+
MA13.02 - Session Introduction
12:01 - 12:02 | Presenter: Jii Bum (Joy) Lee
- Abstract
Loading... -
+
MA13.03 - Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies
12:02 - 12:07 | Presenter: Sai-Hong Ignatius Ou
- Abstract
Loading... -
+
MA13.04 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
12:07 - 12:12 | Presenter: Yun Fan
- Abstract
Loading... -
+
MA13.05 - TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions
12:12 - 12:17 | Presenter: Igor Odintsov
- Abstract
Loading... -
+
MA13.06 - Discussant
12:17 - 12:27 | Presenter: Lorenza Landi
- Abstract
Loading... -
+
MA13.07 - TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
12:27 - 12:32 | Presenter: Benjamin Levy
- Abstract
Loading... -
+
MA13.08 - A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation
12:32 - 12:37 | Presenter: Jonathan Riess
- Abstract
Loading... -
+
MA13.09 - Time from Immune Checkpoint Inhibitor to Sotorasib Use Correlates with Risk of Hepatotoxicity in Non-small Cell Lung Cancer
12:37 - 12:42 | Presenter: Sagar Rakshit
- Abstract
Loading... -
+
MA13.10 - Discussant
12:42 - 12:52 | Presenter: Paolo Bironzo
- Abstract
Loading... -
+
MA13.11 - Live Q&A
12:52 - 13:00
- Abstract
Loading...
